SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nukkleus Inc. (NUKK) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 8/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NUKK
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-35.29
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.00 |
$9.7M |
$-260K |
-2.7% |
| 2017 |
$0.00 |
$24M |
$-137K |
-0.6% |
| 2018 |
$-0.03 |
$19.2M |
$-212K |
-1.1% |
| 2019 |
$-0.03 |
$19.2M |
$-730K |
-3.8% |
| 2020 |
$0.00 |
$19.2M |
$-101K |
-0.5% |
| 2021 |
$-0.13 |
$19.29M |
$-936.85K |
-4.9% |
| 2022 |
$-1.65 |
$21.51M |
$-11.85M |
-55.1% |
| 2023 |
$-13.84 |
$16.22M |
$-17.43M |
-107.4% |
| 2024 |
$-0.59 |
$5.91M |
$-8.52M |
-144.1% |
| 2025 |
$-35.29 |
$0.00 |
$-71.18M |
- |
